<DOC>
	<DOCNO>NCT02314689</DOCNO>
	<brief_summary>The purpose study assess maximum tolerate dose , safety pharmacokinetics investigational drug , intravenous ( IV ) citrulline , subject steady-state sickle cell disease .</brief_summary>
	<brief_title>A Dose Escalation Study Intravenous L-citrulline Steady-state Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>Sickle cell disease genotype ( HbSS , HbS/β° thalassemia , HbS/β+thalassemia , HbSC ) Presence acute illness define fever &gt; 100.4° F within past 48 hour Presence sickle cell pain crisis define presence pain require oral parental opioid therapy . Presence acute chest syndrome presence complication relate sickle cell disease require hospitalization splenic sequestration , hepatic sequestration , stroke , avascular necrosis hip/shoulder , acute priapism , patient diabetes etc . Severe anemia ( hemoglobin &lt; 5g/dL ) History red blood cell transfusion within last 14 day Systemic steroid therapy within last 48 hour Pregnant ( confirm negative urine pregnancy test ) lactate female Alanine/aspartate transferase &gt; 2x upper limit normal laboratory range age . Elevated serum creatinine &gt; 1.5mg/dL Patients inability give consent exclude Medications known contraindicate use Lcitrulline ( concurrent use hydroxyurea allow ) . History diabetes due risk electrolyte imbalance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>